Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

Samsung Biologics signs additional development and manufacturing agreement with STCube


SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate.

STM418 received much attention from the biopharma industry earlier this year upon publication in the Cancer Research Journal. Through preliminary studies, STCube reported that STM418, which selectively masks glycosylation site N58 on PD-1, potently inhibits PD-1/PD-L1 binding to enhance anti-tumor immunity.

Under the development and manufacturing agreement, Samsung Biologics will offer full scope of CDO services from cell line development, process development, non-clinical & clinical material manufacturing, to IND submission for global clinical trials of STM418.

"We look forward to getting fast IND approval for our novel PD-1 antibody through this extended partnership with Samsung Biologics, a world-class CDMO," said Hyun-jin Jung, CEO of STCube. "We will commence global clinical trials to prove the enhanced efficacy compared to existing PD-1 antibodies."

Samsung Biologics CDO business has been growing at a tremendous pace since its launch in 2018 with a high number ? over 50% ? of clients returning for additional business collaboration. STCube, another returning client, had entered into its first CDO partnership with Samsung Biologics in March this year for an immuno-oncology molecule, STT-003.

"We are grateful to STCube for this extended partnership and for recognizing our development expertise and our dedication to bringing client products to market faster and better," said Dr. Tae Han Kim, CEO of Samsung Biologics.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With a flawless regulatory approvals record, the largest capacity at a single site, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit www.samsungbiologics.com

About STCube, Inc.

STCube, Inc. (KRX: 052020.KQ), headquartered in Seoul, South Korea, is an innovative global biopharmaceutical company devoted to developing the next generation of anti-cancer immunotherapy. For more information, visit www.stcube.com

Media Contact
Claire Kim
cair.kim@samsung.com

SOURCE Samsung Biologics


These press releases may also interest you

at 00:15
UAE-based eyewear e-commerce player eyewa, has raised a pre-series B bridge round of US$2.5million from Wamda Capital, EQ2 Ventures and Nuwa Capital. This is eyewa's third funding round, it comes hard-on-the-heels of a mid-2019 Series A round of...

at 00:01
Coca-Cola European Partners (CCEP), the world's largest Coca-Cola bottler based on revenue, has signed a multiyear agreement with IBM to accelerate its transformation to an open hybrid cloud...

at 00:00
Genomenon announced today that CEO Mike Klein has been named to TechCEOs list of "Top 25 Biotechnology CEOs of 2020". Klein was recognized for leading Genomenon, one of the most innovative health IT companies in genomics. Genomenon's AI-powered...

at 00:00
Implementing the IMDRF Codes: Essential Adverse Event Reporting Changes An FDAnews Webinar Thursday, Aug. 20, 2020, 1:30 p.m.-3:00 p.m. EDT https://www.fdanews.com/imdrfcodes Beginning September 7, the FDA will require devicemakers to use a new...

10 aoû 2020
Total (China) Investment (the Company) has signed a Memorandum of Understanding (MoU) in order to pursue strategic collaboration with Alibaba Group ("Alibaba") and leverage their respective resources to drive the digital transformation of the...

10 aoû 2020
Issued by: AU Optronics Corp. Issued on: August 10, 2020 Hsinchu, Taiwan, August 10, 2020? At the Display Week 2020 online exhibition, Dr. Frank Ko, AUO President and Chief Operating Officer, delivered an online keynote speech titled "Display...



News published on 11 july 2020 at 20:00 and distributed by: